BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/30/2017 7:24:03 AM | Browse: 959 | Download: 2826
Publication Name World Journal of Nephrology
Manuscript ID 33475
Country United States
ISSN 2220-6124 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Urology & Nephrology
Manuscript Type Basic Study
Article Title Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease
Manuscript Source Invited Manuscript
All Author List William E Sweeney, Philip Frost and Ellis D Avner
Funding Agency and Grant Number
Funding Agency Grant Number
the PKD research program is provided by the Children’s Research Institute, the Lillian Goldman Charitable Trust, Ellsworth Family and Children’s Foundation of Children’s Hospital and Health System of Wisconsin
Corresponding Author Ellis D Avner, MD, Emeritus Professor of Pediatrics and Physiology, Founding Director, Children’s Research Institute, Children’s’ Hospital Health System of Wisconsin and the Medical College of Wisconsin, Medical College of Wisconsin, Suite C-510, Mailstop CCC C510, 999 North 92nd Street, Milwaukee, WI 53226, United States. bsweeney@mcw.edu
Key Words Autosomal recessive; Autosomal dominant; Polycystic kidney disease; Therapy; Kinase inhibition; Multi-kinase inhibitor; Phosphorylation; Renal cysts; Biliary; G-protein coupled receptor
Core Tip This study examined the effect of a multi-kinase inhibitor, tesevatinib (TSV) on cyst development and growth in rodent models of autosomal recessive polycystic kidney disease (ARPKD). Tesevatinib which targets epidermal growth factor receptors, Src and KDR is currently in clinical trials for autosomal dominant polycystic kidney disease (ADPKD) and given the molecular and cellular interactions of the ADPKD and ARPKD genes and proteins we sought to determine if TSV would ameliorate ARPKD in two well described models and an orthologous rat model of ARPKD phenocopy. Of particular interest was the effect of TSV’s inhibition of VEGFR2 or KDR during early post-natal development and renal maturation.
Publish Date 2017-06-30 06:51
Citation Sweeney WE, Frost P, Avner ED. Tesevatinib ameliorates pro¬gression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease. World J Nephrol 2017; 6(4): 188-200
URL http://www.wjgnet.com/2220-6124/full/v6/i4/188.htm
DOI http://dx.doi.org/10.5527/wjn.v6.i4.188
Full Article (PDF) WJN-6-188.pdf
Full Article (Word) WJN-6-188.doc